Literature DB >> 6149919

The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans.

T R Marten, G R Bourne, G S Miles, B Shuker, H D Rankine, V N Dutka.   

Abstract

The absorption, metabolism, and excretion of 14C-labeled xamoterol (ICI 118,587) has been examined in mice, rats, rabbits, dogs, and humans. There was incomplete absorption by all species after oral administration, ranging from 9% by humans to 36% by dogs. Most of the absorbed radioactivity was eliminated within 24 hr of administration and the renal route predominated. Conjugates of the parent compound were the only observed metabolites in urine, the phenolic glucuronide being the principal animal metabolite and the phenol sulfate being the only human metabolite. There were marked interspecies variations in metabolite patterns and dogs were the only animal species in which the sulfate metabolite was detected. Comparison of the urinary metabolite patterns also showed higher output of the conjugates after oral administration than after intravenous administration, indicating that first pass metabolism was taking place. Little significant change in absorption or metabolism was seen over a range of oral doses; in rats, some saturation of the glucuronide-conjugating mechanism was observed but the sulfate-conjugating mechanism showed little, if any, diminished capacity at high dose levels in dogs. The use of fast atom bombardment mass spectroscopy for the determination of the molecular weight of conjugates is described.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149919

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.

Authors:  E V Sorensen; O Faergeman; M Day; W Bastain
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

3.  Stereoselective metabolism of RS-albuterol in humans.

Authors:  T Walle; E A Eaton; U K Walle; G R Pesola
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

4.  Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.

Authors:  W Bastain; M J Boyce; L E Stafford; P B Morton; D A Clarke; H F Marlow
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol.

Authors:  T Walle; U K Walle
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

6.  Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans.

Authors:  W L Chiou; H Y Jeong; S M Chung; T C Wu
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

7.  Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients.

Authors:  H F Marlow; F L Hine; H M Snow; H Pouleur; M F Rousseau
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

8.  Renal effects of xamoterol in patients with moderate heart failure.

Authors:  H E Bøtker; H K Jensen; L R Krusell; E V Sørensen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

9.  The effect of age and cardiac failure on xamoterol pharmacokinetics.

Authors:  A K Scott; J Webster; J C Petrie; W Bastain
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.